Do analysts prefer PCSA or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PCSA or BFRI more profitable?

Heatwurx has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -394.25% -244.46% Biofrontera -13.78% -145.81% -31.30%

Do analysts recommend PCSA or LPCN?

Lipocine has a consensus price target of $4.00, suggesting a potential upside of 88.68%. Given Lipocine's stronger consensus rating and higher possible upside, analysts clearly believe Lipocine is more favorable than Heatwurx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lipocine 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PCSA or LPCN more profitable?

Heatwurx has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -394.25% -244.46% Lipocine -755.39% -64.75% -57.62%

Do analysts prefer EGRX or PCSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EGRX or PCSA more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A Heatwurx N/A -394.25% -244.46%

Do analysts recommend PCSA or CYCN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer PCSA or CTXR?

Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 779.35%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Heatwurx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is PCSA or CTXR more profitable?

Citius Pharmaceuticals' return on equity of -59.57% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -394.25% -244.46% Citius Pharmaceuticals N/A -59.57% -34.47%

Heatwurx (PCSA) Competitors

$1.91 +0.03 (+1.60%)

Closing price 09/23/2026 03:54 PM Eastern

Extended Trading

$1.91 0.00 (0.00%)

As of 09/23/2026 07:54 PM Eastern

Compare

PCSA vs. BFRI, LPCN, EGRX, CYCN, and CTXR

Should you buy Heatwurx stock or one of its competitors? Heatwurx's main competitors and comparable companies include Biofrontera (BFRI), Lipocine (LPCN), Eagle Pharmaceuticals (EGRX), Cyclerion Therapeutics (CYCN), and Citius Pharmaceuticals (CTXR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Heatwurx compare to Biofrontera?

Heatwurx (NASDAQ:PCSA) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biofrontera has higher revenue and earnings than Heatwurx. Biofrontera is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A
Biofrontera	$41.71M	0.41	-$10.54M	-$0.45	N/A

91.9% of Heatwurx shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 3.5% of Heatwurx shares are held by insiders. Comparatively, 8.1% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Biofrontera had 3 more articles in the media than Heatwurx. MarketBeat recorded 3 mentions for Biofrontera and 0 mentions for Heatwurx. Heatwurx's average media sentiment score of 0.00 equaled Biofrontera'saverage media sentiment score.

Company	Overall Sentiment
Heatwurx	Neutral
Biofrontera	Neutral

Heatwurx has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Heatwurx has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-394.25%	-244.46%
Biofrontera	-13.78%	-145.81%	-31.30%

Summary

Biofrontera beats Heatwurx on 9 of the 13 factors compared between the two stocks.

How does Heatwurx compare to Lipocine?

Heatwurx (NASDAQ:PCSA) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

91.9% of Heatwurx shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 3.5% of Heatwurx shares are held by insiders. Comparatively, 4.7% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Heatwurx has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Lipocine has a consensus price target of $4.00, suggesting a potential upside of 88.68%. Given Lipocine's stronger consensus rating and higher possible upside, analysts clearly believe Lipocine is more favorable than Heatwurx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Lipocine had 7 more articles in the media than Heatwurx. MarketBeat recorded 7 mentions for Lipocine and 0 mentions for Heatwurx. Lipocine's average media sentiment score of 0.64 beat Heatwurx's score of 0.00 indicating that Lipocine is being referred to more favorably in the news media.

Company	Overall Sentiment
Heatwurx	Neutral
Lipocine	Positive

Lipocine has higher revenue and earnings than Heatwurx. Lipocine is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A
Lipocine	$1.98M	8.82	-$9.63M	-$1.79	N/A

Heatwurx has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-394.25%	-244.46%
Lipocine	-755.39%	-64.75%	-57.62%

Summary

Lipocine beats Heatwurx on 11 of the 15 factors compared between the two stocks.

How does Heatwurx compare to Eagle Pharmaceuticals?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Heatwurx (NASDAQ:PCSA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

In the previous week, Eagle Pharmaceuticals had 1 more articles in the media than Heatwurx. MarketBeat recorded 1 mentions for Eagle Pharmaceuticals and 0 mentions for Heatwurx. Eagle Pharmaceuticals' average media sentiment score of 0.48 beat Heatwurx's score of 0.00 indicating that Eagle Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
Heatwurx	Neutral

Eagle Pharmaceuticals' return on equity of 0.00% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Heatwurx	N/A	-394.25%	-244.46%

Eagle Pharmaceuticals has higher revenue and earnings than Heatwurx. Heatwurx is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.05	$35.64M	$1.18	0.76
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Heatwurx has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.9% of Heatwurx shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Heatwurx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Eagle Pharmaceuticals beats Heatwurx on 9 of the 12 factors compared between the two stocks.

How does Heatwurx compare to Cyclerion Therapeutics?

Heatwurx (NASDAQ:PCSA) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Heatwurx has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -87.96% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-394.25%	-244.46%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

91.9% of Heatwurx shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 3.5% of Heatwurx shares are held by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cyclerion Therapeutics has higher revenue and earnings than Heatwurx. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A
Cyclerion Therapeutics	$2.07M	7.89	-$3.53M	-$1.66	N/A

Heatwurx has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

In the previous week, Cyclerion Therapeutics had 1 more articles in the media than Heatwurx. MarketBeat recorded 1 mentions for Cyclerion Therapeutics and 0 mentions for Heatwurx. Heatwurx's average media sentiment score of 0.00 equaled Cyclerion Therapeutics'average media sentiment score.

Company	Overall Sentiment
Heatwurx	Neutral
Cyclerion Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cyclerion Therapeutics beats Heatwurx on 8 of the 11 factors compared between the two stocks.

How does Heatwurx compare to Citius Pharmaceuticals?

Heatwurx (NASDAQ:PCSA) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, Citius Pharmaceuticals had 2 more articles in the media than Heatwurx. MarketBeat recorded 2 mentions for Citius Pharmaceuticals and 0 mentions for Heatwurx. Heatwurx's average media sentiment score of 0.00 equaled Citius Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Heatwurx	Neutral
Citius Pharmaceuticals	Neutral

Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 779.35%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Heatwurx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Citius Pharmaceuticals' return on equity of -59.57% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-394.25%	-244.46%
Citius Pharmaceuticals	N/A	-59.57%	-34.47%

91.9% of Heatwurx shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 3.5% of Heatwurx shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Heatwurx has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.

Heatwurx has higher earnings, but lower revenue than Citius Pharmaceuticals. Heatwurx is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A
Citius Pharmaceuticals	$7.11M	2.20	-$37.43M	-$1.67	N/A

Summary

Citius Pharmaceuticals beats Heatwurx on 11 of the 13 factors compared between the two stocks.

Get Heatwurx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCSA vs. The Competition

Export

Metric	Heatwurx	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.20M	$12.59B	$7.32B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-0.45	792.28	274.01	25.69
Price / Sales	N/A	859.95	667.24	93.60
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	0.78	10.62	10.44	6.32
Net Income	-$13.56M	$2.81B	$3.49B	$359.73M
7 Day Performance	3.24%	0.73%	0.51%	1.35%
1 Month Performance	-8.17%	-1.67%	-3.38%	-3.68%
1 Year Performance	-64.35%	3.07%	16.04%	5.56%

Heatwurx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCSA Heatwurx	1.5694 of 5 stars	$1.91 +1.6%	N/A	-64.3%	$5.20M	N/A	N/A	12	Positive News
BFRI Biofrontera	0.718 of 5 stars	$1.32 +6.5%	N/A	+20.8%	$18.42M	$41.71M	N/A	94	News Coverage Analyst Downgrade
LPCN Lipocine	3.1437 of 5 stars	$2.21 -0.5%	$15.00 +578.7%	-23.2%	$18.30M	$1.57M	N/A	14	News Coverage Analyst Forecast Analyst Revision
EGRX Eagle Pharmaceuticals	N/A	$1.29 flat	N/A	-73.3%	$16.69M	$257.55M	1.09	100	News Coverage Gap Down
CYCN Cyclerion Therapeutics	0.7738 of 5 stars	$3.49 +3.9%	N/A	-83.5%	$16.33M	$2.07M	N/A	30	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCSA) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heatwurx (PCSA) Competitors

PCSA vs. BFRI, LPCN, EGRX, CYCN, and CTXR

How does Heatwurx compare to Biofrontera?

Summary

How does Heatwurx compare to Lipocine?

Summary

How does Heatwurx compare to Eagle Pharmaceuticals?

Summary

How does Heatwurx compare to Cyclerion Therapeutics?

Summary

How does Heatwurx compare to Citius Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA vs. The Competition

Heatwurx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Heatwurx (PCSA) Competitors

PCSA vs. BFRI, LPCN, EGRX, CYCN, and CTXR

How does Heatwurx compare to Biofrontera?

Do analysts prefer PCSA or BFRI?

Which has higher valuation & earnings, PCSA or BFRI?

Do institutionals and insiders hold more shares of PCSA or BFRI?

Does the media prefer PCSA or BFRI?

Which has more risk and volatility, PCSA or BFRI?

Is PCSA or BFRI more profitable?

Summary

How does Heatwurx compare to Lipocine?

Do insiders & institutionals have more ownership in PCSA or LPCN?

Which has more risk and volatility, PCSA or LPCN?

Do analysts recommend PCSA or LPCN?

Does the media refer more to PCSA or LPCN?

Which has preferable valuation & earnings, PCSA or LPCN?

Is PCSA or LPCN more profitable?

Summary

How does Heatwurx compare to Eagle Pharmaceuticals?

Does the media prefer EGRX or PCSA?

Is EGRX or PCSA more profitable?

Which has higher valuation and earnings, EGRX or PCSA?

Do analysts prefer EGRX or PCSA?

Which has more risk and volatility, EGRX or PCSA?

Do insiders and institutionals believe in EGRX or PCSA?

Summary

How does Heatwurx compare to Cyclerion Therapeutics?

Is PCSA or CYCN more profitable?

Do institutionals & insiders hold more shares of PCSA or CYCN?

Which has preferable earnings & valuation, PCSA or CYCN?

Which has more volatility & risk, PCSA or CYCN?

Does the media refer more to PCSA or CYCN?

Do analysts recommend PCSA or CYCN?

Summary

How does Heatwurx compare to Citius Pharmaceuticals?

Does the media favor PCSA or CTXR?

Do analysts prefer PCSA or CTXR?

Is PCSA or CTXR more profitable?

Do institutionals & insiders hold more shares of PCSA or CTXR?

Which has more risk & volatility, PCSA or CTXR?

Which has preferable valuation & earnings, PCSA or CTXR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA vs. The Competition

Heatwurx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools